MediWound to Report Second Quarter 2024 Financial Results

Rhea-AI Summary

MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, has announced it will release its Q2 2024 financial results on August 14, 2024. The company will host a conference call and webcast at 8:30 am Eastern Time on the same day to discuss the results and provide corporate updates.

Investors and interested parties can join the call using the following details:

• Toll-Free: 1-833-630-1956
• Israel: 1-80-921-2373
• International: 1-412-317-1837

A webcast link is also available, and an archived version will be accessible on MediWound's website for replay after the call.

Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time

YAVNE, Israel, Aug. 02, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the second quarter ended June 30, 2024 on Wednesday, August 14, 2024.

Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates, and answer questions.

Dial-in and call details are as follows:

Conference Call & Webcast Details
Toll-Free:	1-833-630-1956
Israel:	1-80-921-2373
International:	1-412-317-1837
Webcast:	Click HERE

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.  An archived version of the webcast will be available for replay on the Investors section of the MediWound website.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of rapid and effective biologics that improve existing standards of care and patient experiences, while reducing costs and unnecessary surgeries.

MediWound’s first drug, NexoBrid^®, is an FDA and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, which can significantly reduce surgical interventions. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline, including the company’s lead drug under development, EscharEx^®. EscharEx is a Phase III-ready biologic for the debridement of chronic wounds, offering significant potential advantages over the dominant $360+ million product and an opportunity to expand the market.

For more information visit www.mediwound.com and follow the Company on LinkedIn.

MediWound Contacts:
Hani Luxenburg	Daniel Ferry
Chief Financial Officer	Managing Director
MediWound Ltd.	LifeSci Advisors, LLC
ir@mediwound.com	daniel@lifesciadvisors.com
Media Contact:
Ellie Hanson
FINN Partners for MediWound
ellie.hanson@finnpartners.com
929-588-2008

FAQ

When will MediWound (MDWD) release its Q2 2024 financial results?

MediWound (MDWD) will release its Q2 2024 financial results on Wednesday, August 14, 2024.

What time is MediWound's (MDWD) Q2 2024 earnings call scheduled for?

MediWound's (MDWD) Q2 2024 earnings call is scheduled for Wednesday, August 14, 2024, at 8:30 am Eastern Time.

How can investors join MediWound's (MDWD) Q2 2024 earnings call?

Investors can join MediWound's (MDWD) Q2 2024 earnings call by dialing 1-833-630-1956 (Toll-Free), 1-80-921-2373 (Israel), or 1-412-317-1837 (International). A webcast option is also available.

Will there be a replay available for MediWound's (MDWD) Q2 2024 earnings call?

Yes, an archived version of the webcast will be available for replay on the Investors section of the MediWound (MDWD) website after the call.